They HAVE completed a number of Phase 1's and those candidates probably ARE years away, but I think the issue was OM for which they SAY they are "poised to enter phase 3 this year". I guess that's the same as “The expedient advancement of Brilacidin-OM into later clinical development is a priority, as is the broader expansion of the complete Brilacidin Franchise.” You decide.
Their OM is infused versus oral and I can't compare the numbers for the two, but this doesn't seem to have been a fully considered reaction: "Galera deal is pre-phase 1. Many years away"
In raising the MRSA issue you obviously also raise the issue of missed opportunities. I hope the analogy isn't the same for OM.
But can it core A apple? Yes Ralph, of course it can core A apple.